Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis
Authors' conclusion
This study provides novel insights into the pathogenesis of RP-ILD development in MDA5+ DM and suggests the plasma protein SPP1 could serve as a potential blood biomarker for RP-ILD early warning.
Study context
- Population
- Patients with anti-MDA5-positive dermatomyositis (DM)discovery: 20 MDA5+ DM, 10 healthy controls (HC)
- Comparison
- MDA5+ DM with rapidly progressive interstitial lung disease (RP-ILD) vs non-RP-ILD vs HC
- Outcome
- Prognostic plasma protein factors for RP-ILD
Methodological detailsLC-MS/MS proteomic discovery, independent enzyme-linked immunosorbent assay (ELISA) validation
- LC-MS/MS proteomic discovery
- Independent ELISA validation
Performance
As reported in the abstract
Plasma protein biomarkers of RP-ILD
Differentially expressed proteins, MDA5+ DM vs HC
413
Proteins changed in RP-ILD vs non-RP-ILD (acute inflammatory response, coagulation, complement cascades)
79
Candidate biomarkers confirmed with ELISA
6
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis. Arthritis Res Ther. Published 2 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →